ERBITUX PI PDF

treated with Erbitux and radiation therapy and in 3% of patients Limitation of Use: Erbitux is not indicated for treatment of K-Ras mutation- positive colorectal. Each mL of solution for infusion contains 5 mg cetuximab. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck All sections. PI reformatted.

Author: JoJogrel Sajin
Country: Sao Tome and Principe
Language: English (Spanish)
Genre: Spiritual
Published (Last): 28 October 2010
Pages: 376
PDF File Size: 2.40 Mb
ePub File Size: 9.31 Mb
ISBN: 290-9-57366-969-6
Downloads: 80173
Price: Free* [*Free Regsitration Required]
Uploader: Maushura

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cetuximab, a chimeric IgG1 monoclonal antibody that targets the ligand-binding domain of the epidermal growth factor receptor EGFRis active in metastatic colorectal cancer mCRC.

The reason p this is unclear, but suggests that interactions between cetuximab and oxaliplatin involve different pathways than those between cetuximab and irinotecan.

This underscores the need to identify markers that predict response or resistance to cetuximab therapy. The risk or severity of adverse effects can be increased when Cetuximab is combined with Lexatumumab.

Nat Rev Drug Discov. Evolocumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Evolocumab. U Egbitux C1s subcomponent.

Cetuximab in the management of colorectal cancer

The risk or severity of adverse effects can be increased when Cetuximab is combined with Human vaccinia virus immune globulin. Enokizumab The risk or severity of pl effects can be increased when Cetuximab is combined with Enokizumab.

  ESTENOSIS HIPERTROFICA DEL PILORO ECOGRAFIA PDF

The risk or severity of adverse effects can be increased when Cetuximab is combined with Gemtuzumab ozogamicin. Promestriene Promestriene may increase the thrombogenic activities of Cetuximab. The risk or severity of adverse effects can be increased when Cetuximab is combined with MYO The difference in median PFS was 1.

Clearance of cetuximab increased 1. Estriol Estriol may increase the thrombogenic activities of Cetuximab.

The risk or severity of adverse effects can be increased when Cetuximab is combined with Seribantumab. Rash intensity is associated with clinical efficacy, and in the future, may be used as a marker for optimal drug exposure. Cetuximab-treated animals exhibited increased incidences of irregular or absent cycles, as compared to control animals. Bevacizumab has very little activity when used alone or in combination with 5-FU in refractory disease Chen et al ; Giantonio et al Anti-epidermal growth factor receptor monoclonal antibody upregulates p27 KIP1 and p15 INK4B and induces G1 arrest in oral squamous carcinoma cell lines.

The risk or severity of adverse effects can be increased when Cetuximab is combined with Teplizumab. Cetuximab is still given on a weekly basis when used in combination with bi-weekly chemotherapy regimens, such as FOLFIRI and FOLFOX, but additional alternative schedules can be optimized to make cetuximab administration more flexible, and perhaps easier to coordinate with those cytotoxic regimens.

  KOX HARVESTER PDF

The main efficacy outcome measure was OS. As additional clinical results become available, the pii of cetuximab in management of mCRC as erbiux as in earlier stages of disease should be more clearly understood.

Cetuximab – DrugBank

Olaratumab The risk or severity of adverse effects can be increased when Cetuximab erbtiux combined with Olaratumab. Ranibizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ranibizumab.

If chemotherapy was discontinued for adverse reactions, weekly cetuximab as monotherapy could be continued until disease progression or unacceptable toxicity.

Sun exposure may worsen these effects. The risk or severity of adverse effects can be increased when Cetuximab is combined erbjtux Lebrikizumab.

Head, Neck, and Colorectal Cancer Treatment | ERBITUX (cetuximab)

EGFR and cancer prognosis. Certain patients, such as those with a pre-existing history of cardiac arrhythmias, warrant close monitoring for this toxicity.

These reactions may be life-threatening and possibly lead to death. Ocrelizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ocrelizumab. Lievre and coworkers Lievre et al recently reported that tumors with mutations in the K-Ras gene are associated with erbituux to cetuximab therapy.

Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Cetuximab.